aTYR PHARMA INC — Director's Dealing 2023

Apr 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2023-04-26

Reporting Person: SCHIMMEL PAUL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-26	Common stock	M	6000	—	Acquired	8890	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-26	Restricted Stock Unit	$	M	6000	Disposed		Common Stock (6000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	113023	Indirect
Common stock	679143	Indirect

Footnotes

F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022.

F2: RSUs convert into common stock on a one-for-one basis.

F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the
sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.

F4: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the
Schimmel Revocable Trust U/A Dtd 9/6/2000.

F5: The RSUs fully vested one year from the grant date which was April 26, 2022.